FDA decision pending on Eli Lilly’s oral weight loss drug orforglipron, a key regulatory milestone for NYSE:LLY. Company planning a US$3b investment in China to manufacture orforglipron locally and ...
Source Link- Like
- Comment
- Favorite
Eli Lilly Weight Loss Push Weighs On Valuation And Growth Hopes
Simply Wall St.06:05
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Like
Report
Login to post
No comments yet